Attached files

file filename
EX-23.1 - EX-23.1 - Ra Pharmaceuticals, Inc.a16-16721_9ex23d1.htm
EX-5.1 - EX-5.1 - Ra Pharmaceuticals, Inc.a16-16721_9ex5d1.htm

 

As filed with the Securities and Exchange Commission on October 25, 2016.

Registration No. 333-    

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM S-1

 

REGISTRATION STATEMENT

Under

The Securities Act of 1933

 


 

RA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware

 

2834

 

26-2908274

(State or other jurisdiction of
incorporation or organization)

 

(Primary Standard Industrial
Classification Code Number)

 

(I.R.S. Employer
Identification Number)

 

87 Cambridge Park Drive

Cambridge, MA 02140

(617) 401-4060

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 


 

Douglas A. Treco, Ph.D.

President and Chief Executive Officer

87 Cambridge Park Drive

Cambridge, MA 02140

(617) 401-4060

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 


 

Copies to:

 

Kingsley L. Taft, Esq.
Ryan S. Sansom, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000

 

David C. Lubner
Executive Vice President
and Chief Financial Officer
Ra Pharmaceuticals, Inc.
87 Cambridge Park Drive
Cambridge, Massachusetts 02140
(617) 401-4060

 

Peter N. Handrinos, Esq.
Brandon J. Bortner, Esq.
Latham & Watkins LLP
John Hancock Tower
200 Clarendon Street
Boston, Massachusetts 02116
(617) 948-6000

 


 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, check the following box.  o

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  x File No. 333-213917

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o

 

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer

o

 

Accelerated Filer

o

 

 

 

 

 

Non-Accelerated Filer

x

(Do not check if a smaller reporting company)

Smaller Reporting Company

o

 


 

CALCULATION OF REGISTRATION FEE

 

 

 

 

 

 

 

 

 

 

Title of Each Class of Securities
to be Registered

 

Amount to be
Registered(1)

 

Proposed Maximum
Offering Price Per
Share

 

Proposed Maximum
Aggregate Offering
Price(2)

 

Amount of
Registration Fee(3)

 

Common Stock, par value $0.001 per share

 

1,436,615

 

$

13.00

 

$

 18,675,995

 

$

2,165

 

(1)              Represents only the additional number of shares being registered and includes 187,385 shares of common stock issuable upon exercise of the underwriters’ option to purchase additional shares. Does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1 (File No. 333-213917).

(2)              The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price. The registrant previously registered securities at an aggregate offering price not to exceed $93,380,000 on a Registration Statement on Form S-1 (File No. 333-213917), which was declared effective by the Securities and Exchange Commission on October 25, 2016. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of $18,675,995 is hereby registered, which includes shares issuable upon the exercise of the underwriters’ option to purchase additional shares.

 


 

This Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) promulgated under the Securities Act.

 

 

 



 

EXPLANATORY NOTE AND INCORPORATION BY REFERENCE

 

This registration statement is being filed with respect to the registration of additional shares of common stock, par value $0.001 per share, of Ra Pharmaceuticals, Inc., a Delaware corporation, pursuant to Rule 462(b) under the Securities Act of 1933, as amended. The contents of the earlier registration statement on Form S-1 (File No. 333-213917), which was declared effective by the Commission on October 25, 2016, are incorporated in this registration statement by reference.

 

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on the 25th day of October, 2016.

 

 

RA PHARMACEUTICALS, INC.

 

 

 

 

By:

/s/ Douglas A. Treco

 

 

Douglas A. Treco, Ph.D.

 

 

President, Chief Executive Officer and Principal Executive Officer

 

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-1 has been signed by the following person in the capacities and on the date indicated.

 

Name

 

Title

 

Date

 

 

 

 

 

/s/DOUGLAS A. TRECO

 

Director, President, Chief Executive Officer and Principal Executive Officer

 

October 25, 2016

Douglas A. Treco, Ph.D.

 

 

 

 

 

 

 

 

/s/DAVID C. LUBNER

 

Executive Vice President, Chief Financial Officer and Principal Financial and Accounting Officer

 

October 25, 2016

David C. Lubner

 

 

 

 

 

 

 

 

*

 

Director

 

October 25, 2016

Peter Tuxen Bisgaard

 

 

 

 

 

 

 

 

 

*

 

Director

 

October 25, 2016

Markus Goebel, M.D., Ph.D.

 

 

 

 

 

 

 

 

 

*

 

Director

 

October 25, 2016

Robert Heft, Ph.D.

 

 

 

 

 

 

 

 

 

*

 

Director

 

October 25, 2016

Jason Lettmann

 

 

 

 

 

 

 

 

 

*

 

Director

 

October 25, 2016

Edward T. Mathers

 

 

 

 

 

 

 

 

 

*

 

Director

 

October 25, 2016

Timothy R. Pearson

 

 

 

 

 

 

 

 

 

*

 

Director

 

October 25, 2016

Rajeev Shah

 

 

 

 

 

*       Pursuant to Power of Attorney

 

By:

/s/ DOUGLAS A. TRECO

 

 

Douglas A. Treco, Ph.D.

 

 

Attorney in Fact

 

 

3



 

EXHIBIT INDEX

 

Exhibit
No.

 

Exhibit Index

 

 

 

5.1

 

 

Opinion of Goodwin Procter LLP

 

 

 

 

23.1

 

 

Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm

 

 

 

 

23.2

 

 

Consent of Goodwin Procter LLP (included in Exhibit 5.1)

 

 

 

 

24.1

*

 

Power of Attorney

 


*                 Previously filed on the signature page to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-213917), originally filed with the Securities and Exchange Commission on September 30, 2016 and incorporated by reference herein.

 

4